Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Pasithea Therapeutics Corp. Warrant (KTTAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/26/2025: KTTAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -96.43% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/26/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.34 | 52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 |
52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.84% | Return on Equity (TTM) -82.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6931236 |
Shares Outstanding - | Shares Floating 6931236 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pasithea Therapeutics Corp. Warrant
Company Overview
History and Background
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of novel treatments for central nervous system (CNS) disorders. The warrants represent the right to purchase shares of the underlying stock.
Core Business Areas
- CNS Therapeutics Development: Focus on developing novel treatments for neuropsychiatric disorders such as depression and anxiety, potentially involving psychedelics.
Leadership and Structure
Information regarding the specific leadership team and organizational structure for the warrant itself is not directly applicable. Focus is on the parent company, Pasithea Therapeutics.
Top Products and Market Share
Key Offerings
- Warrant: The warrant (US: KTTAW) gives the holder the right to purchase Pasithea Therapeutics Corp. (KTTA) common stock at a specified price within a specified period. Market share data is not applicable to warrants. The value is derived from the underlying stock.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically neuropsychiatric drug development, is highly competitive and regulated. Success depends on clinical trial outcomes, regulatory approvals, and market adoption.
Positioning
Pasithea Therapeutics is positioning itself in the emerging market for psychedelic-assisted therapies and other CNS treatments, focusing on unmet medical needs.
Total Addressable Market (TAM)
The TAM for CNS disorder treatments is substantial, projected in billions of dollars. Pasithea Therapeutics is targeting a niche within this TAM, focusing on specific disorders and treatment modalities.
Upturn SWOT Analysis
Strengths
- Focus on innovative CNS therapies
- Potential for first-in-class treatments
- Partnerships or collaborations with research institutions
Weaknesses
- Early stage of development
- High risk associated with clinical trials
- Dependence on future financing
Opportunities
- Growing market for CNS therapies
- Increasing acceptance of psychedelic-assisted treatments
- Potential for strategic partnerships or acquisitions
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Unsuccessful clinical trial outcomes
- Dilution to shareholders from warrant exercise
Competitors and Market Share
Key Competitors
- ALK (ALK.PA)
- GHRS (GHRS)
- CRL (CRL)
Competitive Landscape
The pharmaceutical industry is highly competitive, requiring strong scientific expertise, clinical execution, and regulatory navigation.
Growth Trajectory and Initiatives
Historical Growth: Growth trajectory depends on the clinical and regulatory progress of Pasithea Therapeutics' drug candidates.
Future Projections: Future projections depend on analyst estimates for Pasithea Therapeutics Corp. (KTTA) and the underlying stock price.
Recent Initiatives: Recent initiatives for Pasithea Therapeutics would include clinical trial progress, partnerships, and financing activities.
Summary
Pasithea Therapeutics Corp. Warrants are a speculative investment whose value is directly tied to the underlying performance of Pasithea Therapeutics. The company is early-stage and faces significant clinical and regulatory risks. Success hinges on positive clinical trial data and successful commercialization of its drug candidates. Warrant holders should be aware of potential dilution and the time-sensitive nature of warrant expiration.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Financial news sources
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in warrants and early-stage companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pasithea Therapeutics Corp. Warrant
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-09-15 | CEO & Director Dr. Tiago Reis Marques M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.pasithea.com |
Full time employees 4 | Website https://www.pasithea.com | ||
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.